ABSTRACT: Collagen IV is the major protein found in basement membranes. It comprises three heterotrimers (a1a1a2, a3a4a5, and a5a5a6) that form distinct networks, and are responsible for membrane strength and integrity. We constructed linear maps of the collagen IV heterotrimers (''interactomes'') that indicated major structural landmarks, known and predicted ligandbinding sites, and missense mutations, in order to identify functional and disease-associated domains, potential interactions between ligands, and genotype-phenotype relationships. The maps documented more than 30 known ligand-binding sites as well as motifs for integrins, heparin, von Willebrand factor (VWF), decorin, and bone morphogenetic protein (BMP). They predicted functional domains for angiogenesis and haemostasis, and disease domains for autoimmunity, tumor growth and inhibition, infection, and glycation. Cooperative ligand interactions were indicated by binding site proximity, for example, between integrins, matrix metalloproteinases, and heparin. The maps indicated that mutations affecting major ligandbinding sites, for example, for Von Hippel Lindau (VHL) protein in the a1 chain or integrins in the a5 chain, resulted in distinctive phenotypes (Hereditary Angiopathy, Nephropathy, Aneurysms, and muscle Cramps [HANAC] syndrome, and early-onset Alport syndrome, respectively). These maps further our understanding of basement membrane biology and disease, and suggest novel membrane interactions, functions, and therapeutic targets.
Introduction
The collagens represent the major proteins of the extracellular matrix and 29 types (I-XXIX) assembled from at least 44 distinct a-chains have been identified [Myllyharju and Kivirikko, 2004; Soderhall et al., 2007] . Each molecule is a homo-or heterotrimer of three a-chains with the characteristic Gly-Xaa-Yaa repeat sequence where Xaa and Yaa are often proline and hydroxyproline. Collagens serve as scaffolds for the attachment of cells and matrix proteins, but are increasingly recognized to have many other ligands and be highly biologically active [Di Lullo et al., 2002; Sweeney et al., 2008; Timpl, 1989] .
Collagen I
Collagen I is the most abundant protein in the body and contributes to the structural integrity of many tissues. It is a fibrillar molecule that comprises a heterotrimer of two a1 and one a2 chains encoded by the COL1A1 and COL1A2 genes. Collagen I has more than 100 different ligands, as diverse as bone morphogenetic protein (BMP), von Willebrand factor (VWF), and interleukin 2 [Di Lullo et al., 2002; Myllyharju and Kivirikko, 2004; Sweeney et al., 2008] . It is affected by mutations resulting in osteogenesis imperfecta and other connective tissue disorders, and also by glycation in diabetes and aging.
Collagen I Interactome
Linear protein maps (''interactomes'') of the collagen I a1a1a2 heterotrimer have documented novel structural features and ligand-binding sites, predicted new interactions and functions, and summarized the molecule's diverse biological functions [Sweeney et al., 2008] . The maps demonstrated major ligandbinding regions, a ''cell interaction'' domain that regulates integrin-mediated cell binding and fibril remodeling, and a ''matrix interaction'' domain that determines crosslinking, proteoglycan interactions, and tissue mineralization. These maps suggested critical functional sites colocalize within such domains and that domain-specific, ligand-mediated functions were likely to be cooperative. For example, the proximity of sites for integrinbinding and collagenase cleavage predicted fibril remodeling disrupts cell-fibril interaction; and the colocalization of binding sites for fibronectin, fibrillogenesis, and collagenase cleavage suggested a role for fibronectin in collagen assembly and degradation. Importantly, the collagen I map also correlated mutations in the a1 and a2 chains and clinical phenotypes in osteogenesis imperfecta (MIM 166200) [Marini et al., 2007; Sweeney et al., 2008] . Hundreds of missense mutations have been described, and the corresponding phenotypes vary from mild and asymptomatic, to severe with multiple, frequent fractures. Some of this variation is explained by mutation location and the nature of the substituting residues. Mutations closer to the carboxyl terminus generally result in more severe disease because disrupted helix propagation temporarily exposes residues amino-terminal to the site on all three chains to excessive hydroxylation and glycosylation [Engel and Prockop, 1991] . Severe disease also results from mutations where glycine is substituted with larger residues, such as valine, or more highly charged residues, such as aspartic acid [Byers et al., 1991; Marini et al., 2007] . Even singlepoint mutations influence the mechanical behavior of these tissues. Mutations associated with the most severe phenotypes correlate with weakened intermolecular adhesion, increased intermolecular spacing, reduced stiffness, and reduced strength of collagen fibrils . However, the linear collagen I map provided evidence for a third mechanism for genotype-phenotype correlations: namely, that severe disease was more likely when missense mutations affected major structural or ligand-binding sites [Marini et al., 2007; Scott and Tenni, 1997; Sweeney et al., 2008] .
Collagen IV
In contrast to collagen I, collagen IV forms networks, and is widely expressed in vascular and other basement membranes. The collagen IV family comprises six homologous a-chains, a1-a6, encoded by the COL4A1-COL4A6 genes. These have arisen by reduplication from the ancestral COL4A1 gene and are divided into two families-COL4A1-like (the a1, a3, and a5 chains), and COL4A2-like (the a2, a4, and a6 chains), where the corresponding genes share exon-intron organization, exon size, sequence homology, and the proteins have common structural features. Each collagen IV chain consists of the typical helical intermediate sequence as well as noncollagenous (NC) domains at the amino and carboxyl termini and multiple short noncollagenous interruptions [Khoshnoodi et al., 2008; Netzer et al., 1998 ]. The heterotrimers assemble intracellularly beginning with disulfide bond formation at the carboxyl terminal NC1 and progressing towards the 7S domain. They are then secreted to form a supramolecular network through dimerization at the carboxyl terminus and tetramerization at the 7S domain [Siebold et al., 1988] , and the networks are further stabilized by lateral associations [Yurchenco and Ruben, 1987] .
Collagen IV is found as three distinct heterotrimers in separate networks. The a1a1a2 network is ubiquitous in embryonic life and persists in vascular and other membranes (including brain, proximal renal tubule, muscle) in adulthood, but in specialized membranes in the glomerulus, lung, cochlea and retina is replaced in infancy by the a3a4a5 network, and by the a5a5a6 network in the epidermis, testis, and Bowman's capsule. The a1a1a2 and a3a4a5 networks are critical in embryogenesis, angiogenesis, and haemostasis, tumor growth and invasion, and microbial infection, and the a3a4a5 network, in particular, is responsible for the integrity of fluid-membrane barriers. The role of the a5a5a6 network is less clear.
The collagen IV networks are also affected in inherited and other diseases. Inherited diseases are most often due to missense mutations and associated with vascular or renal abnormalities. Mutations in the a1 chain result in stroke, porencephaly, (MIM 175780) and the Hereditary Angiopathy, Nephropathy, Aneurysms, and muscle Cramps syndrome (HANAC; MIM 611773) syndrome [Gould et al., 2005; Plaisier et al., 2007; Sibon et al., 2007] . Heterozygous mutations in the a3 or a4 chains produce Thin Basement Membrane Nephropathy (TBMN) with isolated hematuria, or rarely, autosomal dominant Alport syndrome (MIM 104200) with renal failure and hearing loss. Homozygous or compound heterozygous mutations in the a3 or a4 chains result in autosomal recessive Alport disease (MIM 203780) with renal failure, hearing loss, lenticonus, and retinopathy. Hemizygous mutations in the a5 chain cause X-linked Alport syndrome (MIM 301050) . No disease-producing missense mutations have been described in the a2 or a6 chains.
The most clinically significant of these diseases is X-linked Alport syndrome. It affects one in 5,000 individuals, and more than 200 missense mutations have been described to date. Again, missense mutations affecting the carboxyl terminal residues of the a5 chain or where glycine is replaced by larger or more highly charged residues result in a severe phenotype with end-stage renal failure before the age of 30 [Gross et al., 2002; Jais et al., 2000; Persikov et al., 2004] . However it is still not always possible to predict the clinical course from the nature of the underlying mutations.
The a3a4a5 network is also affected by autoantibody-mediated rapidly progressive glomerulonephritis (antiGBM disease or ''Goodpasture syndrome'') [Saus et al., 1988] . Sometimes alloantibodies to components of the a3a4a5 network develop in X-linked Alport syndrome after renal transplantation leading to graft failure. In addition, the collagen IV networks are affected by glycation in diabetes and aging, and this alters matrix flexibility, proteolytic susceptibility, and subsequent function [Mott et al., 1997; Reigle et al., 2008; Tarsio et al., 1987] .
Construction of the Collagen IV Interactomes
We have constructed linear maps of the three collagen IV heterotrimers indicating major structural landmarks, known and predicted ligand-binding sites, and missense mutations, in order to demonstrate potential functional domains and ligand interactions, and explain genotype-phenotype variation in inherited disease.
The human reference sequences (NP_001836, a1 isoform 1; NP_001837, a2; NP_000082, a3 isoform 1; NP_000083, a4; NP_000486, a5 isoform 1; and NP_001838, a6 isoform 1) were aligned as the a1a1a2, a3a4a5 and a5a5a6 heterotrimers in Microsoft Word according to the carboxyl terminal NC1 sequences with their 12 conserved cysteine residues, the triple helix NC interruptions, and the 7S domains using the Clustal W function of MacVector 9.0 (Accelrys). The collagen IV a1, a3, a5, and a6 chains also undergo alternative splicing. Isoform 1 represents the canonical sequence (Supp . Table S1 ), and other isoforms differ by small insertions to large deletions.
Structural domains and sites related to collagen IV assembly and turnover were identified from the literature and open access bioinformatics web sites (Uniprot, UCSC, etc.). Binding sites for integrins, cells, extracellular matrix molecules, and other ligands were identified from the literature, Web sites (Uniprot, UCSC, BioGrid, MINT, STRING, etc. ) , and by reference to the collagen I maps [Di Lullo et al., 2002; Matthews et al., 2009; Sweeney et al., 2008] . Some sites were predicted from binding motifs. Others were derived from rotary shadowing electron microscopy measurements using the assumption that the average spacing of residues on the triple helix was 0.238 nm [Pietz and Reddi, 1984] . Still others were derived from experiments demonstrating binding to collagen IV proteolytic fragments or mimetic peptides. These were considered relevant because some ligands bind only to denatured collagen in vivo. In studies using collagen IV from the EngelbrethHolm-Swarm (EHS) tumor, which comprises only the a1a1a2 heterotrimer, and where the chain was not identified, binding was presumed to occur to the more abundant a1 chain.
Sites involved in the major functions of the collagen IV networks (endothelial and epithelial cell binding domains, angiogenesis, hemostasis) or in disease (tumor growth and invasion, antitumor, microbial infection, glycation, and autoimmune disease) were indicated on the maps.
The consequences of missense mutations affecting major structural sites, ligand-binding sites, and functional domains of the collagen IV networks were then investigated. Missense variants were identified from the literature and open access Web databases (UniProt; Embl; HMGD database/Biobase, NCBI, etc.). Variants were classified as ''pathogenic'' or ''nonpathogenic'' by their contributors. Pathogenic missense variants in the a1-a5 chains were examined to determine whether those affecting a major structural domain or ligand-binding site were more likely to produce a distinctive clinical phenotype. In particular, whether mutations causing HANAC (a1 chain), autosomal dominant Alport syndrome rather than thin basement membrane nephropathy (a3 and a4 chains), or X-linked Alport syndrome with juvenile-(before the age of 30) or adult-onset end-stage renal failure were due to mutations affecting a major structural domain or ligand-binding site.
In addition, the distribution of a5 sequence variants was examined for randomness. Briefly, mutational densities for each exon were calculated and compared with simulated mutational maps consistent with the ''null hypothesis'' of no spatial variation. Exons with an unusually high or low density relative to the null distribution were then analyzed in more detail, and contiguous exons were further studied to increase the power of testing.
Collagen IV a1a1a2, a3a4a5, and a5a5a6 Interactomes (Figs. 1A-C)
Structural Landmarks and Sites Related to Assembly and Remodeling
The signal peptide at the amino terminal 7S domain directs posttranslational transport but is subsequently cleaved. The cysteine and lysine residues beyond the signal peptide form crosslinks through disulfide and lysine-hydroxylysine bonds respectively to produce the tetramer [Khoshnoodi et al., 2008] . Each a-chain has a collagenous Gly-Xaa-Yaa sequence, where Xaa and Yaa are often proline and hydroxyproline, as well as a number of short (1-24 residue) noncollagenous interruptions ranging from 21 in the a1 chain to 26 in the a4 chain. These confer flexibility and possibly have a role in connecting with supramolecular partners. The 7S kink is located 60 nm (about 250 residues) from the amino terminus on rotary shadowing [Pietz and Reddi, 1984] . Glycosylation is critical in protein folding and stability. N-glycosylation requires the Asp-Xaa-Ser/Thr sequence [Spiro, 2002] . O-glycosylation is more common and occurs at serine, threonine, hydroxylysine, and hydroxyproline residues within the collagenous domain without requiring specific sequences. Hydroxylation is a prerequisite for glycosylation, and there are about 50 hydroxylysine-linked disaccharides in each collagen chain [Hudson et al., 1993] . Prolines and lysines in the Yaa position are hydroxylated. Hydroxyprolines are underlined in the a1 chain in Figure 1A but have not been described for the other chains. We have used the term O for hydroxyproline rather than P where this was used in the original report, but O and P are generally interchangeable for collagen IV. There are also some-X-4Hyp-Ala sequences in the chains. The interaction of prolyl 4-hydroxylase clearly depends on the amino acid in the Xaa position and proline is particularly favorable, but alanine, leucine, arginine, valine, and glutamate are too. Hydroxylation is catalyzed mainly by prolyl 4-hydroxylase, and less often by prolyl 3-hydroxylase or lysyl 5-hydroxylase. If hydroxylation does not occur, the unfolded chain remains bound to the enzyme within the endoplasmic reticulum. Peptide-linked lysine is hydroxylated to form 5-hydroxylysine that then attaches glucosyl and galactosyl residues. Hydroxylysyl residues are also modified to form crosslinks and failure of lysine hydroxylation prevents tetramer formation.
The NC1 domain comprises the carboxyl terminal 230 residues that fold to form the globular NC1 domain. Crosslinking results in a hexamer that can be dissociated into monomer and dimer subunits. The dimers are held together by covalent S-hydroxylysine-methionine crosslinks between methionine and hydroxylysine residues in opposite chains [Vanacore et al., 2005 [Vanacore et al., , 2009 . The 12 cysteines in each NC1 domain form intramolecular disulfide bonds. The domain swapping residues in the 13 residue donor b-hairpin motif and the 15-residue acceptor docking site with genetic hypervariability result in selective formation of heterotrimers [Khoshnoodi et al., 2006a] . The hypervariable regions of the a2 and a5 chains are critical in the formation of the a1a1a2 and a3a4a5 heterotrimers, respectively [Kang et al., 2007; Khoshnoodi et al., 2006b ].
The highly complex folding and assembly of the collagen IV triple helix requires the coordination of many endoplasmic reticulum-based enzymes and molecular chaperones including HSP47 [Koide et al., 2006] and probably Secreted Protein, Acidic, and Rich in Cysteine (SPARC) [Martinek et al., 2007] . The collagen molecule moves from the endoplasmic reticulum to the Golgi body in partnership with HSP47 [Canty and Kadler, 2005] . HSP47 recognizes GXR where R is critical, and all potential binding sites occur in the triple helix. The GXR sequence is found at multiple locations in each chain ranging from 12 in the a5 to 26 in the a2 chain. HSP47 may compete for binding with prolyl 4-hydroxylase [Asada et al., 1999] . The (GPP) 4 sequence near the a3a4a5 carboxyl terminus may function in triple helix nucleation [Hyde et al., 2006] as well as platelet binding as discussed later.
Collagen IV is remodeled by enzymatic cleavage in embryogenesis and angiogenesis, as a result of normal turnover, as well as in tumor invasion and spread. It is degraded by a specific group of matrix metalloproteinases (MMP-2, -3, -9, -10,-13, -19, and -26; [Somerville et al., 2003] and by serine proteinases. MMP-2 and -9 are the major collagen IV collagenases. They have a common cleavage site in the a1 (G/I at residue 446) and a2 (G/L at residue 463) chains [Hostikka and Tryggvason, 1988] . These overlap with sites for integrin binding, and integrins appear important in MMP activation . These motifs are conserved in other collagen IV chains. MMP-3 and -9 cleave asymmetrically between G/F and G/L on adjacent a1 and a2 chains leaving the NC1 domains intact [Gioia et al., 2009; Mott et al., 1997] . Predicted MMP-13 cleavage sites are at GPVGMK (near residue 990) and 
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GPMGLK (residue 1003) in the a2 chain, and at GPIGLS (residue 85) in the a4 chain [Deng et al., 2000] . Collagen IV is also cleaved by neutrophil proteinase 3, elastase (MMP-12), and cathepsins K, B, S, and possibly L. Neutrophil proteinase 3 cleaves at V/E, S/V, S/L, and Q/L [Rao et al., 1991] , and there are many potential cleavage sites for these motifs except Q/L in each chain. Cathepsin K cleaves at G/K and is particularly important in chain turnover [Garnero et al., 1998; Nosaka et al., 1999] .
Collagen IV also undergoes intracellular proteasomal degradation. Ubiquitin covalently attaches to a KG sequence, and the binding of multiple ubiquitins results in degradation. The KG site has only been described for the a3 chain in the triple helix near the NC1 domain (Uniprot), but this motif is conserved in all the chains.
Integrin-Binding Sites (Fig. 2)
Integrins mediate cell adhesion to all basement membrane proteins including collagen IV. The collagen IV integrin receptors belong to the b1 subgroup, namely, a1b1 and a2b1 [Leitinger and Hohenester, 2007; White et al., 2004] . Binding triggers pathways involved in cell migration and invasion, including phosphorylation of FAK, paxilin, activation of small G-proteins, PKC, and PI3 kinase as well as changes in intracellular calcium levels.
Collagen IV has 3 major integrin-binding motifs: GFOGER, which is the commonest and also occurs in fibrillar collagen; the classical RGD site; and other non-RGD binding motifs (Supp .  Table S2 ). Integrin-binding sites are distributed throughout each heterotrimer, and the location of sites is important because receptor clustering appears to be necessary for activation. Some sites are cryptic and only accessible after denaturation, proteolysis etc. For example, cleavage of collagen IV during angiogenesis results in the loss of a1b1 but gain of avb3 binding . RGD sites are present at multiple locations in the collagenous domains [Kim et al., 1994] , but are generally inaccessible to cells in the native molecule [Herbst et al., 1988; Kim et al., 1994] .
Integrins a1b1/a2b1: a major site for binding of a1b1 and a2b1 integrins has been identified within the triple-helical cyanogen bromide-derived fragment, CB3, located 100 nm from the aminoterminus of collagen IV [Vandenberg et al., 1991] . Antibodies to this fragment block cell binding by 80%. Subsequently, a single a1b1 and two a2b1 integrin binding sites were predicted on this fragment [Kern et al., 1993] . Further refinement identified a conformational-dependent site formed by the unique whole collagen heterotrimer spatial arrangement of the three residues, two Asp461 on the a1 chains and Arg 461 on the a2 chain, as critical for a1b1 integrin binding . More recently, functional activity of this a1b1 binding site was confirmed using synthetic triple-helical peptides corresponding to residues 457-468 of the a1 and a2 chains stabilized with an artificial cysteine knot [Renner et al., 2004] .
The precise identity and structure of the a2b1 binding site(s) in collagen IV remains unknown. A potential candidate is the GFOGER sequence identified as an integrin binding site in collagen I [Knight et al., 1998 ]. Interestingly, both the a1b1 and a2b1 integrins recognize GFOGER as the minimal binding motif on collagen [Knight et al., 2000; Siljander et al., 2004] . However, the a1b1 integrin binds with higher affinity to collagen IV, and a2b1 to collagen I [Kern et al., 1993; Tulla et al., 2001; Zhang et al., 2003] . The a2b1 integrin recognizes GXO/SGER, and then a hierarchy of GFPGER4GLPGER4GMPGER4GAPGER, and GLOGER and GASGER [Siljander et al., 2004] . The F is not critical for binding. There are no GLPGER, GASGER, GMPGER, GQRGER, GASGQR, or GFPGEK sequences in collagen IV. The most amino terminal GFOGER site on the a1 chain may represent the principal site for endothelial cell binding and activation [Knight et al., 2000; Xu et al., 2000] , and for angiogenesis [Sweeney et al., 2008] . The a2b1 site on the a1 chain appears to facilitate lung cancer cell adhesion [Khoshnoodi et al., 2008] .
Integrins a10b1 and a11b1: chondrocytes and fetal muscle cells adhere to collagen IV through these integrins [Tiger et al., 2001; Zhang et al., 2003 ], but the sites are unknown [Tulla et al., 2001; Zhang et al., 2003 ].
Integrin avb3: there are three binding sites at the carboxyl terminus of the a3 chain, two within the NC1 domain. The carboxyl terminal KRGDS site within the triple helix represents the only functional RGD cell-binding site in collagen IV [Pedchenko et al., 2004] . It mediates adhesion of podocytes [Borza et al., 2008] , and overlaps with the binding site for the Goodpasture protein-binding protein (GPBP) [Raya et al., 1999] . A second non-RGD avb3 site located in the amino terminal part of the a3NC1 domain has antiangiogenic activity [Maeshima et al., 2002; Sudhakar et al., 2003] . The third site in the carboxyl terminal part of the a3NC1 (amino acids 185-203) has antitumor activity, and colocalizes with the CD47/ IAP (integrin-associated protein) [Han et al., 1997; Shahan et al., 1999] . It also inhibits the activation of human neutrophils [Monboisse et al., 1994] , inhibits the proliferation, and induces apoptosis of, capillary endothelial cells, and reduces tumor growth in vivo . Both avb3 sites within the NC1 domain of the a3 chain are brought into close proximity by the b-hairpin binding to VR3, sufficient for activation. Both also overlap with heparin-binding sites which may enhance cell binding to the membrane through cell-surface proteoglycans.
The NC1 domains of the a1, a2, a3, and a6 chains all have antiangiogenic properties Kamphaus et al., 2000; Petitclerc et al., 2000] that are attributed to integrin binding sites in at least the a1 and a3 chains [Sudhakar and Boosani, 2008; Sudhakar et al., 2005] . In the a1 chain, anti-angiogenic activity is mediated by the a1b1 integrin binding within the carboxyl terminal half of the NC1 domain [Nyberg et al., 2008] .
Integrin a3b1: one site for a3b1 binding has been identified in the triple helical domain using a synthetic peptide corresponding to residues 531-543 of the a1 chain [Miles et al., 1995] . Interestingly, this peptide promoted adhesion of melanoma and ovarian carcinoma cell lines in single-stranded conformation, thus providing the first evidence for existence of triple-helix-independent integrin binding sites within the collagenous domain. Another a3b1 site is located at the carboxyl a3 NC1 domain and overlaps with the non-RGD avb3 binding site, suggesting that the a3b1 integrin trans-dominantly inhibits avb3 function [Borza et al., 2006; Hodivala-Dilke et al., 1998 ]. The antitumor activity of this region has been confirmed [Sudhakar and Boosani, 2008] .
Cell-Binding Sites
The collagen IV networks in basement membranes bind all cells except erythrocytes. The a1a1a2 heterotrimer is usually anchored in vascular membranes to endothelial cells, but interacts also with neutrophils, lymphocytes, and platelets, as well as lung, breast, kidney, and colon tumor cells, and bacteria. In the kidney glomerulus, the a3a4a5 heterotrimer interacts specifically with glomerular epithelial and endothelial cells. Binding occurs through integrin and nonintegrin-mediated mechanisms. Tumor cells bind using the same integrins as endothelial cells. Integrin-mediated cell adhesion is promoted by the heparan sulfate side chains of perlecan, glypican, and syndecans, as well as glycoprotein VI and VWF. 
Endothelial cells
Endothelial cells typically bind collagen IV through the a1b1 and a2b1 integrins but also via avb3 and other integrins [Marneros and Olsen, 2001; Pedchenko et al., 2004 Pedchenko et al., , 2005 Tsilibary et al., 1990] . The major endothelial cell binding sites in the a1a1a2 hetrotrimer are the GFOGER sequences in the more amino terminal triple helix, and the TAGSCLRKFSTM peptide derived from the a1 NC1 domain promotes adhesion and spreading of bovine endothelial cells [Tsilibary et al., 1990] . There are similar motifs to this in all the other collagen IV NC1 domains.
Epithelial cells
Glomerular, retinal, and probably other epithelial, as well as endothelial, cells bind to the KRGDS avb3 integrin-binding site in the a3 chain triple helix adjacent to the NC1 domain [Borza et al., 2008; Pedchenko et al., 2004] . No other epithelial-specific binding sites have been identified.
Neutrophils
Neutrophils bind to the avb3 integrin binding site in the a3 NC1 domain, and binding downregulates neutrophil activation and, probably decreases tissue damage as the cells traverse the capillary wall [Monboisse et al., 1994] .
Platelets
Platelets adhere to collagens I and III through the a1b1 and a2b1 integrin receptors, and adhesion is enhanced by binding to the glycoprotein VI and VWF receptors. Collagen IV has binding sites for these integrins and glycoprotein VI as well as predicted sites for VWF.
Molecules That Enhance Platelet and Cell Binding

Cell surface proteoglycans
Heparin and heparan sulfate proteoglycan (HSPG) binding sites potentially support cell-collagen IV interactions through binding to cell surface HSPGs such as syndecan and glypican. Some sites have been demonstrated experimentally and others predicted from Cardin and Weintraub [1989] consensus sequences. However, the predicted sequences are probably only active in an a-helix, which is not found in the triple helical regions of collagen IV.
SPARC (osteonectin or BM-40)
This small glycoprotein modulates cell-matrix interactions and collagen assembly [Mayer et al., 1991] . It is essential for embryonic development and may also function as a chaperone. In collagen I, the GVMGFO motif where F is critical for binding [Hohenester et al., 2008 ] is a common binding site for SPARC, VWF, and the discoidin domain receptor 2 (DDR2), but this site is not found in collagen IV. In collagen IV, SPARC recognizes GFP or GLP [Hohenester et al., 2008] but it is unclear whether VWF and DDR1 (collagen IV binds DDR1 not DDR2) also bind to this motif.
Von Willebrand factor (VWF)
vWF is a large, multimeric molecule that mediates platelet adhesion to collagen, and is a carrier for coagulation factor VIII. The binding motif on collagen III is RGQPGVMGF [Lisman et al., 2006] and in collagen IV similar motifs occur on the a2 (RGQPGVPGVPGMKGD), a1, a4 (RGQPGEMGD), and, possibly, the a3 (RGQPGRKGL) chains. This presumes the homotrimeric structure found in collagen III is not necessary for binding. These motifs do not include the GFP or GLP sequences needed for SPARC binding and, if confirmed, must represent an independent binding mechanism.
Glycoprotein VI
The binding of glycoprotein VI to collagen I tethers and activates platelets prior to the platelet release reaction [Dubois et al., 2006] . The (GPP) 4 sequence simultaneously binds and activates two glycoprotein VI molecules [Smethurst et al., 2007] . The a1, a4, and a6 chains each have a single glycoprotein VI binding site but at different locations in the amino, midpoint, or carboxyl terminus, of the triple helix. Only the a1a1a2 heterotrimer has two glycoprotein VI binding sites, and these are at the amino terminus of the a1 triple helix, between binding sites for SPARC and a1b1/ a2b1 integrin. This represents a potential platelet binding site. Sites in the other heterotrimers may have other functions such as triple helix nucleation or stabilization.
Binding to Extracellular Matrix Structural Proteins
Collagen IV interacts with laminin, nidogen, and HSPG (mainly perlecan, but also chondroitin and dermatan sulfate, and agrin). Molecules bind at multiple sites sometimes by different mechanisms. The following locations have been determined mainly from rotary shadowing electron microscopy, and some are unconfirmed.
Laminin
Laminin is the major noncollagenous protein found in basement membranes. It forms a distinct network that binds to the collagen networks directly [McKee et al., 2007] or through a nidogen bridge.
Laminin binding to collagen IV has been studied by rotary shadowing in the EHS tumor and there are up to six sites throughout the a1a1a2 heterotrimer (Supp . Table S3 ) [Aumailley et al., 1989; Charonis et al., 1985; Laurie et al., 1986; Ohno et al., 1991; Rao et al., 1985] . The sites 251-291, 174-178, and 75-87 nm from the NC1 have been confirmed in at least two studies, and potentially overlap with sites for nidogen, HSPG, and fibronectin.
Nidogen (''entactin'')
Nidogen is ubiquitous in basement membranes and links the collagen IV and laminin networks [Aumailley et al., 1989] . Only one binding site, 80 nm from the NC1 domain, which is potentially shared with HSPG, has been identified [Aumailley et al., 1989] .
HSPG sites
There are two major binding sites for HSPG in the collagen IV triple helix. These are 200-300 nm and 100 nm from the NC1 [Koliakos et al., 1989; Laurie et al., 1986] . A further site in the NC1 domain has the highest affinity and binds preferentially to chondroitin or dermatan sulphate.
Heparin is a glycosaminoglycan with repeating disaccharide subunits of glucosamine and sulfated iduronic or glucuronic acids that represents a structural analog of HSPG. Three potential heparin-binding motifs have been identified in collagen IV [Koliakos et al., 1989] . These are termed Hep-I in the a1 chain (TAGSCLRKFSTM), Hep-II in a2 (LAGSCLARFSTM), and Hep-III in a1 (GEFYFDLRLKGDK). The Hep-III site overlaps with a laminin/HSPG/fibronectin site identified on rotary shadowing. The following sequences are analogous to the Hep-I and Hep-II sites: TLGSCLQRFTTM in a3; LAGSCLPVFSTL in a4; and TAGSCLRRFSTM in a5. These are located in the NC1 domains close to, or overlapping with, integrin-binding sites.
Further potential heparin-binding sites have the sequences XBBXBX and XBBBXXBX, where B are basic and X are hydropathic residues [Cardin and Weintraub, 1989] . They include GRRGKT (residues 830-835) in the a3 chain, and GKRGKP and NKRAHG (residues 296-300 and 1,489-1,495, respectively) in the a5 chain.
Melanoma cell/CD44 receptor
CD44 is a chondroitin sulfate PG that is a receptor on the surface of melanoma cells, and binds to the a1 chain (GVKGDKGDPGYPGAP) [Lauer-Fields et al., 2003 ].
Other Molecules That Bind to Type IV Collagen
Bone morphogenetic protein 4 (BMP4)
This cytokine is a member of the TGF-b superfamily and regulates vascular endothelium proliferation, differentiation, and survival. It is critical in embryogenesis and vascular remodeling, and in macrophage and T cell responses [Wang et al., 2008] . Its binding motif (Y/FI/VSRCXVCE) appears at the same location within the NC1 domain in all collagen IV chains [Wang et al., 2008] . BMP4 binds heparin [Paralkar et al., 1990] and the sites for BMP are near binding sites for heparin on all the collagen IV chains.
Fibronectin
Fibronectin binding is controversial but rotary shadowing studies suggest a site 205 nm from the NC1 domain on the a1a1a2 heterotrimer at about residue 580 [Laurie et al., 1986] . Fibronectin typically binds via an RGD motif and is enhanced by HSPG [Tarsio et al., 1987] . The proposed location overlaps with a possible HSPG site.
Usherin
Binding to collagen IV occurs at the hinge region between the 7S domain and the triple helix [Bhattacharya et al., 2004] where there are multiple disulfide bonds. It is not clear whether usherin binds to one or all collagen IV chains, but it is found in the same membranes as the a3a4a5 heterotrimer (the stria vascularis of the cochlea and Bruch's membrane in the retina) and has been added her to both the a1a1a2 and a3a4a5 maps. Usher's syndrome results from mutations in the corresponding gene and causes retinitis pigmentosa and hearing loss but not renal disease.
Von Hippel Lindau (VHL) protein
VHL protein acts as a tumor suppressor in two major pathways: the hypoxia-inducible factor (HIF) a and an extracellular matrix pathway. The VHL-HIFa interaction requires HIFa hydroxylation by cytosolic prolyl hydroxylases. In cells with mutant VHL, HIFa accumulates and its targets, VEGF and TGF-a are activated [Kurban et al., 2008] . VHL protein binds to both the a1 and a2 chains of unassembled intracellular collagen IV [Grosfeld et al., 2007] . Binding to the a2 chain is specific and also depends on hydroxylation [Kurban et al., 2008] . The VHL protein interacts with the 70 kDa amino terminal fragment of the a2 chain protruding from the endoplasmic reticulum. This represents a domain at about residues 500-600 near the 3 0 hydroxylated residues on the a2 chain. VHL also binds to fibronectin and the proposed location contains a fibronectin-binding site [Ohh et al., 1998 ]. The potential VHL binding domain corresponds to the region affected by mutations affecting the a1 chain and responsible for HANAC.
Factor IX
The active form of this serine protease hydrolyses and activates Factor X. Factor IX may have a role in coagulation during endothelial membrane rupture. It binds to the a1 chain at residues 985-1,092 and 1,182-1,288, and to the a2 chain at residues 1,030-1,137 and 1,227-1,333 [Cheung et al., 1996; Wolberg et al., 1997] . Mutations in this protein result in hemophilia B.
Prolactin-related protein 1
This glycoprotein is produced by the placenta, binds to the collagen IV 7S domain, and probably acts on cells traversing the placenta [Takahashi et al., 2008] .
Many other proteins are also found in the basement membrane and bind to collagen IV but their binding motifs are not known (Table 1) .
Functional and Disease-Associated Domains
The collagen IV heterotrimers play critical roles in both physiological and disease states. Digested or denatured collagen fragments may have different roles from the native molecule if functional sites have been destroyed and cryptic sites exposed and activated. The a1a1a2 heterotrimer is the most susceptible of the collagen molecules to proteolysis.
Angiogenesis regulatory domains
Angiogenesis is critical in embryogenesis, and in the adult, in tissue regeneration and wound healing. It depends on the interaction of endothelial cells with extracellular matrix proteins or their fragments, as well as with growth factors, such as the VHL protein.
A major putative angiogenesis regulatory site is present at the amino terminus of the triple helix of the a1 chain. In collagen I, endothelial cell ligation of the a1b1/a2b1 integrin-binding motif, GFOGER, in the triple helix induces angiogenesis [Sweeney et al., 2008] and this motif is also present in the collagen IV a1 chain. It is near binding sites for laminin/HSPG/fibronectin, SPARC, VHL protein, and predicted sites for heparin and VWF. Fragments of the triple helix containing the GFPGER motif inhibit angiogenesis by preventing endothelial cell binding to GFPGER in the native collagen IV.
The collagen IV NC1 domains also represent major angiogenesis regulatory domains because they have binding sites for endothelial cell integrins, and HSPG/heparin. Although integrin binding sites in the NC1 are angiogenic, the same sites on the fragments produced by, for example, MMP cleavage during membrane turnover, are anti-angiogenic. Thus, the NC1 domains of the a1, a2, a3, and a6 chains of collagen IV that result from proteolysis (sometimes known as ''arresten,'' ''canstatin,'' and ''tumstatin'' for the a1-a3 chains, respectively) are all anti-angiogenic [Mundel and Kalluri, 2007; Mundel et al., 2008; Petitclerc et al., 2000] . The a1 NC1 domain disrupts angiogenesis through blocking growth factordependent endothelial cell growth possibly through effects on the a1b1 integrin and perlecan . The a2 NC1 domain inhibits endothelial cell growth and migration, and induces apoptosis . The a3 NC1 domain includes 2 avb3 integrin-binding sites, one with anti-angiogenic and one with antitumor properties Shahan et al., 1999] . One of these NC1 fragments is currently in clinical trials for the treatment of human renal cell carcinoma [Eikesdal et al., 2008] .
Hemostasis
The blood vessel wall stroma comprises mainly collagen I and III, and the endothelial basement membrane is predominantly collagen IV a1a1a2. Platelet adhesion under high shear stress depends on the binding of VWF to collagen, and, in turn, on binding to glycoprotein VI and the a2b1 integrin. Platelets bind to collagen I and III, but have only weak affinity for collagen IV. The two glycoprotein VI sites of the a1a1a2 heterotrimer may [Paraoanu and Layer, 2008] . Stress produces a splice variant, ''acetylcholinesterase-related peptide,'' that binds collagen IV and laminin, and inhibits cell adhesion by competing with other forms of acetylcholinerase [Johnson and Moore, 2007] C1q receptor 1 This molecule is widely expressed on cell surfaces and has a conserved sequence that is homologous with collagen IV but also binds to it [Ghebrehiwet et al., 1992] Collagen type VII The noncollagenous domain of collagen VII binds to collagen IV [Chen et al., 1997] . Mutations cause the blistering disease epidermolysis bullosa Discoidin domain receptor (DDR) DDR1 and 2 are receptor tyrosine kinases that function as collagen receptors. Collagen IV stimulates DDR1 in the absence of integrins [Vogel et al., 2000] but the relevant motif is not known [Khoshnoodi et al., 2008] . The binding motif on collagen I is common to DDR2, SPARC, and VWF Disrupted in schizophrenia 1 (DISC1) This is a multifunctional protein associated with the centrosome and spindle, that binds to many cytoskeletal and signalling receptors and also to collagen IV [Morris et al., 2003] Extracellular matrix protein 1 This is a secreted glycoprotein that binds to collagen IV [Sercu et al., 2008] Fibulin 2, 4 This is a family of 5 extracellular matrix proteins found in close association with microfibrils containing fibronectin or fibrillin. Both fibulin -2 and fibulin-4 bind to collagen IV [Kobayashi et al., 2007; Sasaki et al., 1995] Insulin-like growth factor binding protein 7 (Igfbp7)
Also known as ''angiomodulin,'' interacts with extracellular matrix proteins expressed in most blood vessels, including collagen IV [Nagakubo et al., 2003] Lymphoid chemokines The cytokines CCL21, CXCL13, and CXCL12 are secreted by high endothelial venules and play a critical role in lymphoid trafficking Mac-2 binding protein This is a cell-adhesive protein found in the extracellular matrix [Sasaki et al., 1998 ] Matrilins This family of extracellular adaptor molecules binds to collagen I, fibronectin and the laminin-nidogen complex and possibly also to collagen IV [Mates et al., 2004] Microfibrillar-associated protein 2 This is the major antigen of elastin-associated microfibrils. It may be affected in inherited connective tissues disease [Finnis and Gibson, 1997] Myelin-associated glycoprotein This multifunctional adhesion molecule is found in the central and peripheral nervous system. It binds to fibrillary collagens more avidly than collagen IV possibly through glycosaminoglycans [Fahrig et al., 1987] Nucleosomes These comprise nuclear chromatin and proteins, especially histones, and it is unclear why they bind to extracellular matrix proteins [Mjelle et al., 2007] Oncostatin M This is a cytokine in the IL6 family and binds to collagen I, III, IV, and VI [Somasundaram et al., 2002] Plasminogen This is the precursor of the serine protease plasmin. It binds to the a1 and a2 chains of collagen IV [Stack et al., 1992] Platelet-derived growth factor Some extracellular matrix components interact with growth factors and cytokines thus limiting the location of their biological activities [Somasundaram and Schuppan, 1996] Serpins These serine protease inhibitors inhibit thrombin, urokinase and plasmin. Some including C 0 esterase inhibitor and nexin 1 bind to collagen IV [Donovan et al., 1994] Serum amyloid A This is an acute phase protein of unknown function that binds with high affinity to laminin and lower affinity to type IV collagen [Ancsin and Kisilevsky, 1997] Transforming growth factor b1 This protein is critical in cell proliferation and differentiation and binds to collagen IV [Paralkar et al., 1991] Thrombospondin 1 This is one of a family of thrombospondins released from platelets during aggregation. It is involved in many biological reactions and bind weakly to collagen IV [Galvin et al., 1987] HUMAN MUTATION, Vol. 32, No. 2, [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] 2011 contribute to platelet binding, and these sites are close to the putative integrin, SPARC, and VWF sites.
Infections
Adhesion of microbial pathogens to lectin-like sequences on collagen IV is the initial step in tissue colonization and infection. Many bacteria and fungi including Staphylococcus aureus, Streptoccus pyogenes, Escherichia coli, Yersinia enterocolitica, Candida albicans, and Agaricus bisporus bind to collagen IV through a variety of mechanisms including microbial glycoprotein adherence to lectin-binding domains [Alonso et al., 2001; Dinkla et al., 2009; Farfan et al., 2008; Flugel et al., 1994; Kajimura et al., 2004; Vercellotti et al., 1985] .
The lectin-binding sites are widely dispersed in the different collagen IV chains. Agaricus bisporus agglutinin binds to the a1 NC1 domain [Kajimura et al., 2004] . Escherichia coli binds to the 7S domain of collagen IV in the urinary tract and thus to the a1a1a2 heterotrimer [Selvarangan et al., 2004; Westerlund et al., 1989] . The a2-a5 collagen chains each have a Ca-dependent C-lectin-like domain that overlap in the a3, a4, and a5 chains (Swiss protein Web site). The M3 serotype of Streptococcus pyogenes induces glomerulonephritis and rheumatic heart disease and a bacterial ''peptide associated with rheumatic fever'' (''PARF'') binds to placental type IV collagen, 20 and 100 nm from the 7S domain in the a1a1a2 triple helix resulting in subsequent autoantibody production [Dinkla et al., 2009] .
Tumor growth and spread
Tumor growth and spread depends on the development of an adequate blood supply and migration through the vascular endothelium. Basement membrane collagen is integral to these activities. Tumor cells adhere to collagen IV through integrins and induce angiogenesis. However, the upregulation of integrins also inhibits tumor cell migration [Bago et al., 2009] . The full-length a3 NC1 domain has no effect on tumor cell growth , but the corresponding synthetic peptide (residues 185-203) that binds to a3b1 and CD47/avb3 integrin complex inhibits the proliferation of various epithelial tumor and melanoma cell lines [Han et al., 1997; Maeshima et al., 2000; Shahan et al., 1999] . Surprisingly, recent studies show this peptide also possesses anti-angiogenic activity [Shahan et al., 2004] . Thus, proteolytic degradation of the a3 NC1 may release a cryptic fragment with antitumor activity. The NC1 of the a6 chain also has antitumor activity [Mundel et al., 2008] .
Collagen glycation
Glycation is the nonenzymatic binding of glucose to the e-amino group of lysine, and the subsequent cross-linking of frucosyl-lysine to produce advanced glycation end products. Glycation occurs on many residues but preferentially on hydroxylysine, and is normal in aging and accelerated in diabetes. Glycation of collagen I results in a molecule that is less flexible [Reiser et al., 1992] , and has altered binding to cells and ligands including integrins, HSPG and fibronectin [Reigle et al., 2008; Tarsio et al., 1987] .
The principal residues affected by glycation in collagen IV are not known except for locations in the 7S and NC1 domains of the a1 and a2 chains [Raabe et al., 1996] . These potentially interfere with hexamer formation, and the binding of laminin and usherin. Glycation interferes with collagen IV assembly in diabetes , and with digestion by MMP-3 and MMP-9 [Mott et al., 1997] , and hence, tissue remodeling. Glycation may also contribute to the delayed wound healing and the increased risk of tumor metastasis seen in diabetes and aging.
Elevated glucose levels in diabetes also produce reactive dicarbonyl species (''carbonyl stress''). One of the major products of glucose degradation, methylglyoxal, specifically reacts with arginine residues in proteins. Arginine is a key residue in most integrin binding sites (RGD, GFOGER, etc.) , and modification of collagen IV and its fragments, including RGD-containing fragments of the a3 chain by methylglyoxal, disrupts integrinmediated cell-matrix interactions [Pedchenko et al., 2005] .
Immunoreactive determinants
Epitopes for the autoantibodies in Goodpasture disease, and alloantibodies in Alport posttransplant glomerulonephritis are located within the a3 and a5 NC1 domains [Pedchenko et al., 2010] . The Goodpasture autoepitopes E A and E B comprise a3 NC1 residues 17-31 and 127-141 [Kalluri et al., 1991; Netzer et al., 1999) and at the homologous residues to E A , 17-31, on a5NC1 [Pedchenko et al., 2010] . The Goodpasture T cell epitope overlaps with the E A epitope [Bolton et al., 2005] . The Goodpasture antigenbinding protein (GPBP) is a nonconventional serine/threonine kinase that phosphorylates the KRGDS motif of the a3 chain located just before the NC1 domain [Raya et al., 1999 [Raya et al., , 2000 Revert et al., 2008] . It occurs in two spliced forms, the more active of which is present in tissues affected by Goodpasture disease.
About 5% of patients with X-linked Alport syndrome who receive a kidney transplant develop alloantibodies against Alport antigenic sites that they ''recognize'' immunologically because the a3a4a5 network is absent from their native kidneys. Three alloepitopes have been identified in the NC1 domain of the a5 chain, and two in the linear sequence [Kang et al., 2007] . Other epitopes of Alport alloantibodies with unknown motifs are present in the a3 and a4 chains . The Goodpasture and Alport epitopes overlap, but the Goodpasture epitopes are sequestered (''cryptic'') within the a3a4a5 NC1 hexamer, whereas the Alport epitopes are accessible to alloantibodies, suggesting different key residues [Hudson et al., 2003; Pedchenko et al., 2010] .
Another disease, with severe subepidermal bullous eruptions and renal insufficiency, is associated with IgG autoantibodies directed against an unknown epitope in the NC1 domain of the a5 chain [Ghohestani et al., 2000] .
HLA DR15 binds to FIMFTSAGS in the NC1 domain and is responsible for the specific B and T cell response [Phelps et al., 1998 ]. BMP4 binds nearby in the NC1 and also has potentially a role in the macrophage and T cell response in autoantibodymediated disease.
T lymphocytes bind to a specific site on the a3 chain and this binding is enhanced by lectins [Rabinovich et al., 1999] .
Missense Mutations and Clinical Phenotype
Missense mutations resulting in HANAC are limited to the collagen IV a1 chain binding site for VHL and other proteins (integrins, heparin, VWF) involved in angiogenesis. One known mutation affects an integrin-binding site.
VHL syndrome is characterized by hemangioblastoma of the cerebellum, retina, and spinal cord; renal cysts, and clear cell cancer. Basement membranes in tissues affected by VHL syndrome, including the proximal renal tubule membrane-derived renal cysts and cancer, all comprise the a1a1a2 network. The absence of clinical features from tissues with collagen IV a3a4a5-containing basement membranes suggest the VHL protein does not bind to this network. Inheritance of VHL disease is autosomal dominant but the germline mutation predisposes to a ''second hit'' and loss of the functional protein that normally directs the a2 chain into the heterotrimer. Both HANAC and VHL are characterized by vascular abnormalities and renal cysts, and HANAC probably results from defective binding of the VHL protein to the a1 chain and subsequent loss of function. Mutations elsewhere in the collagen a1 chain result in vascular stroke and porencephaly.
More than 100 mutations have been described in the a3 and a4 chains in autosomal recessive Alport syndrome and thin basement membrane nephropathy. These occur throughout both chains but are too few to determine randomness or explain genotypephenotype variation. Of the nine missense mutations resulting in autosomal dominant Alport syndrome, only a cysteine substitution in the a4 chain NC1 domain (C1634S) is likely to have major structural consequences through affecting disulfide bond and globular domain formation [Marcocci et al., 2009] .
Two hundred thirty-three missense mutations have been described in the a5 chain in X-linked Alport syndrome. Clinical data are available for 105, 73 of which result in severe disease with ''early-onset'' renal failure. Glycine substitutions with glutamic acid, valine, or arginine trend to severe disease (22/33, 67% vs. 9/27, 33%, P 5 0.1755 by Fisher's two-tailed test, Supp. Table S4a and b) . Both mutations affecting an integrin-binding site also result in severe disease, but this may be attributed to the nature of the substituting residue (glutamic acid, valine).
The distribution of mutations in the a5 chain is not random. Mutations are more common in exons 25 and 26 (P 5 0.00348) but do not result in more severe disease and no known ligands bind here. Mutations are underrepresented in exons 1-6 and 42-45 (P 5 0.0006, 0.00078, respectively). The nonrandom distribution of a5 mutations is not due to a nonviable phenotype because the a3a4a5 network is not present in embryonic life and even a5 chain nonsense mutations in males are not lethal.
No missense mutations are known for the a2 and a6 chains. This may be because the phenotype is too severe to be viable, too mild to come to medical attention, or too rare to be detected.
Alternative Splicing Isoforms
Collagen IV isoforms are found in different tissues and it is interesting to consider the consequences of alternative splicing on the retention of major ligand-binding sites and functional domains. For example, the ?1 isoform is missing the major angiogenesis regulatory. The a1 isoform is missing the major angiogenesis regulatory domain and the site affected by mutations in HANAC syndrome. The a3 isoforms 2-4 lack various of the NC1 immunogenic, endothelial cell binding, antiangiogenic, and antitumor domains. Isoforms of the a5 and a6 chains retain all major ligand-binding sites.
Conclusions Structural and Functional Domains
Collagen IV is the major constituent of basement membranes, but the predominant heterotrimer and its binding partners and functions depend on individual tissues. Each of the maps described here documented all known ligand-binding sites from tissues as diverse as blood vessels, placenta, muscle, kidney, small bowel, and skin. More ligands were identified for the a1a1a2 network because it is more widespread, more abundant where it occurs, and has been best studied.
Overall, the carboxyl terminal domains had the highest density of ligand-binding sites, and represented major ligand-binding and often functional domains. There were other lesser ''hotspots.'' There were also regions with few or no ligand-binding sites, such as residues 750-900 in the a1 chain. These may have a structural ''load-bearing'' role or provide space between biologically active regions. Some ligands such as integrins, BMP, and heparin bound at similar locations on different collagen chains.
Integrin-binding sites were most abundant in the a1a1a2 heterotrimer, and endothelial cell binding occurred via the a1b1, a2b1, and avb3 integrins throughout the triple helix and NC1 domains of the a1 and a2 chains. These sites enable the vascular endothelium to adhere to the underlying collagen network. Furthermore, the GFOGER motif ensures cell-directed collagen IV assembly into the basement membrane. The integrins also facilitate binding to other cells including tumor cells and platelets. The a3a4a5 heterotrimer has a distinctive epithelial cell binding site in the triple helix near the NC1 of the a3 chain that is not present in other chains. This is particularly relevant for glomerular, alveolar and retinal epithelial cells which rest on a membrane comprising the a3a4a5 network.
The proximity of binding sites for functionally related ligands on individual or nearby collagen chains suggested cooperative interactions. Integrin receptors span up to 10 nm and the glycosaminoglycan side chains of HSPGs extend 20 nm or more [Doyle et al., 1975] . The collagen heterotrimer itself is 1.0-1.5 nm wide [Trus and Piez, 1980] and ligands binding to vertically aligned sites may also interact [Di Lullo et al., 2002] . The collagen networks represent scaffolds for the clustering of ligands binding to the triple helix, and the NC1 domains form intermolecular aggregates that bring together many ligands. Cooperative binding potentially occurred: between integrin sites, especially in the NC1 domains; between integrins and HSPG side chains, or MMPs; between SPARC and glycoprotein VI; and between the Goodpasture antigen, T cells, HLA DR15 and BMP4.
Modeling the Collagen Type IV Scaffold
The collagen IV maps suggest an orientation with respect to the endothelial and epithelial membrane surfaces in vivo. The collagen IV molecule is 400 nm long with 57 nm between the 7S domain and kink, and 340 nm between the kink and NC1 domain, but basement membranes are typically only 50-300 nm wide. The collagen IV triple helical domains are too long to allow the monomer to lie perpendicular to the outer membrane margin but the noncollagenous interruptions and supercoiling confer some flexibility. Our observation that collagen IV heterotrimers demonstrate polarity with respect to cell and ligand interactions suggests a model for orientation. Thus, in the a1a1a2 heterotrimer, the GFOGER motif at the amino terminus represents the major binding site for vascular endothelium. The kink allows the N-terminal 57 nm of the triple helix to lie flat against the endothelial surface of the basement membrane, and the neighboring 7S domains to self-associate and covalently crosslink. The kink enables the molecule to span, at an acute angle, from the endothelium to the epithelium. In cross-section the molecule is ''accordion-like'' and potentially stabilized by interactions with other extracellular matrix molecules at different levels between the membrane margins. The major binding site for epithelial cells is the avb3 motif in the triple helix near the a3 NC1 domain of the a3a4a5 heterotrimer. This location also allows the N-terminal triple helix to associate near the endothelial surface.
The collagen IV interactomes have been based on ligand interactions with native collagen, at various stages of denaturation, or with synthetic triple helices or peptides. Binding was detected with low resolution rotary shadowing or high-resolution methods. The maps' major limitations were that they did not indicate critical physicochemical characteristics that might be apparent on space filling and other multidimensional maps, and that they did not demonstrate the effect of ligand binding on collagen IV physicostructural properties such as flexibility and elasticity using techniques like ''optical tweezers'' and molecular dynamics measured by coarse grain simulation. Molecular level properties such as chemistry and nanomechanics require a more sophisticated approach, such as multiscale modeling, and more powerful layering than has been possible here. Nevertheless, there is already evidence that mutations in Alport syndrome alter not only the molecular structure but also nanomechanical properties [Srinivasan et al., 2009] .
Future collagen IV interactomes are likely to be specific for tissues and developmental stage, and binding sites will be confirmed using high-resolution methods. These linear protein maps indicate the functional domains responsible for collagen IV's diverse biological activities, and potentially facilitate the development of antagonists for these activities through targeting the corresponding domains.
